Optipharm옵티팜
153710 · KOSDAQ · ₩153710 · 옵티팜
- Market cap
- ₩64B
- Enterprise value
- ₩65B
- P/E
- —
- P/B
- 2.6×
- Dividend yield
- 0.0%
- ROE
- −9.1%
- Net margin
- −9.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−30.4% from the high
₩4,075Today: ₩4,200 – ₩4,400₩6,250
Returns
- 1W−2.2%
- 1M−4.9%
- 3M−4.5%
- 6M−16.5%
- YTD−14.7%
- 1Y−11.1%
- Volume today
- 4,917
- 0.5× the 20-day average
- Traded today
- ₩21M
- Listed shares
- 14,669,958
- EPS (12 months)
- −₩153
- Earnings yield −3.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Optipharm stock overview
Optipharm (옵티팜, KRX: 153710) is listed on KOSDAQ, in the Biotech & Pharma sector. The company has been designated by Korean authorities as an official animal disease diagnostic laboratory since 2006, providing animal disease testing services to national agencies, livestock and poultry farms, universities, research institutes, and veterinary clinics. Its shares closed at ₩4,350 on Oct 27, 2026, down 0.34% on the day, giving it a market value of ₩64B.
Key facts
- Market cap
- ₩64B
- Sector
- Biotech & Pharma
- Latest price change
- −0.34%
- As of
- Oct 27, 2026
- Main business
- The company has been designated by Korean authorities as an official animal disease diagnostic laboratory since 2006, providing animal disease testing services to national agencies, livestock and poultry farms, universities, research institutes, and veterinary clinics.
Quick answers about Optipharm
- What does Optipharm do?
- The company has been designated by Korean authorities as an official animal disease diagnostic laboratory since 2006, providing animal disease testing services to national agencies, livestock and poultry farms, universities, research institutes, and veterinary clinics. It also sells animal medicines, bacteriophage-based feed additives and products for livestock disease prevention, and supplies minipigs for research and related medical applications, with its operations centered in South Korea and limited exports.
- What is the market cap of Optipharm?
- The market capitalisation of Optipharm was ₩64B at the close on Oct 27, 2026.
- Who are the largest shareholders of Optipharm?
- According to the latest official filings, the largest reported holders are Kim Hyun-il (2.12%, as of Sep 18, 2026); National Pension Service (0.44%, as of Dec 31, 2024).
- When is the next earnings report from Optipharm?
- Korean companies rarely announce results dates in advance. Based on when Optipharm filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Optipharm?
- Yes. The National Pension Service held 0.44% of Optipharm shares as of Dec 31, 2024.
Company profile
The company has been designated by Korean authorities as an official animal disease diagnostic laboratory since 2006, providing animal disease testing services to national agencies, livestock and poultry farms, universities, research institutes, and veterinary clinics. It also sells animal medicines, bacteriophage-based feed additives and products for livestock disease prevention, and supplies minipigs for research and related medical applications, with its operations centered in South Korea and limited exports.
Written by AI from the company's latest annual report.
- Korean name
- 옵티팜
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김현일
- Founded
- Jul 2000
- Listed
- Oct 2018
- Listed shares
- 14,669,958
- Fiscal year ends
- Month 12
- Website
- www.optipharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Insider shareholding reportSep 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Investor relations (IR) eventAug 12, 2026
- Insider shareholding reportJun 29, 2026
- Insider shareholding reportMay 29, 2026
Titles in Korean until English translations are added.
Also known as: Optipharm / 옵티팜 / 153710 / KRX:153710
Source: KRX statistical information